From: Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
Pathologic subtype
Pathological response
CR (n = 16)
Non-CR (n = 39)
HR+, HER-2− (n = 31)
8 (25%)
23 (75%)
HR+, HER-2+ (n = 9)
2 (22%)
7 (78%)
HR−, HER-2 + (n = 7)
3 (42%)
4 (58%)
HR−, HER-2− (n = 8)
3 (38%)
5 (62%)